Clinical Trials Browser

INDUSTRY × patritumab deruxtecan × 30 days × Clear all

NCT06596694 2026-06-01

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Phase 1/2 Recruiting

Gastrointestinal

Gastrointestinal Neoplasms

NCT07060807 2026-06-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms

NCT06469944 2026-05-26

MK-3475-06C

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06731907 2026-05-26

MK-3475-01G

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07286149 2026-05-26

MK-3475-01F

Phase 1/2 Recruiting

Lung Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT06797635 2026-05-20

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Phase 2 Recruiting

Breast Neoplasms

NCT04165070 2026-05-18

MK-3475-01A

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

277 enrolled 16 charts

Non-Small Cell Lung Cancer Metastatic

NCT06445972 2026-05-12

MK-3475-06D

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT06941272 2026-05-12

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms